How do you advise patients looking for 2nd opinions while on standard-of-care, first line treatment for metastatic ER+HER2- BC(i.e. a CDK4/6 inhibitor + aromatase inhibitor) to bolster requests for chemotherapy when non indicated?   

This scenario comes up very often in clinical practice. There are many unanswered questions regarding the optimal treatment strategy in this setting. Trials evaluating the optimal treatment sequence and biomarkers driven therapies are urgently needed.  In general, resistance to h...